Summit Therapeutics (SMMT) Set to Announce Earnings on Wednesday

Summit Therapeutics (NASDAQ:SMMT) will be issuing its quarterly earnings data before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Summit Therapeutics (NASDAQ:SMMT) last posted its earnings results on Tuesday, August 6th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Stock Performance

Shares of NASDAQ:SMMT opened at $22.24 on Tuesday. The company’s fifty day moving average is $19.44 and its 200-day moving average is $11.53. Summit Therapeutics has a 52 week low of $1.64 and a 52 week high of $33.89. The company has a market capitalization of $16.11 billion, a PE ratio of -96.69 and a beta of -0.97.

Analyst Ratings Changes

SMMT has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Summit Therapeutics in a report on Friday, October 4th. Citigroup cut Summit Therapeutics from a “buy” rating to a “neutral” rating and raised their price target for the company from $19.00 to $23.00 in a report on Friday, September 27th. Finally, Stifel Nicolaus boosted their price objective on Summit Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th.

Summit Therapeutics Company Profile

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.